Protalix BioTherapeutics, Inc. has completed a private stock placement
Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Bigtincan (ASX:BTH) has successfully raised funds via an institutional placement
Bigtincan Holdings (ASX:BTH) has successfully completed an institutional placement. The raising was completed alongside the recently announced acquisition of ClearSlide, a sales engagement technology platform leader with over 500 customers across three continents. Funds will also be used to support the acquisition integration, working capital and future growth of the company.
Learn moreMizrahi Tefahot has issued bonds worth US$125 million
Mizrahi Tefahot Issuing Company Ltd. has completed a fundraising to refinance and develop the company.
Learn moreDutch Dental Group has raised new acquisition debt from ING Bank to support its growth strategy
Dutch Dental Group (DDG) has raised a new debt financing package provided by ING Bank, consisting of term loans, an acquisition facility and an RCF.
Learn more